<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Percutaneous coronary intervention with intracoronary stents: Overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Percutaneous coronary intervention with intracoronary stents: Overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Percutaneous coronary intervention with intracoronary stents: Overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Dawn Abbott, MD, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Windecker, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Percutaneous coronary intervention (PCI) is a minimally invasive nonsurgical procedure performed to improve blood flow in one or more segments of the coronary circulation. Coronary revascularization with PCI primarily involves the use of balloon angioplasty and intracoronary stenting with drug-eluting stents (DES); other tools to improve coronary blood flow include plaque modification techniques such as atherectomy and lithoplasty. </p><p>This topic will present an overview of the use of stents and DES in particular, including issues related to deployment, periprocedural medication use, and a few procedural and safety issues. Other relevant topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">"Intracoronary stents: Stent types"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83567.html" rel="external">"Bioresorbable scaffold coronary artery stents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1567.html" rel="external">"Specialized revascularization devices in the management of coronary heart disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">BENEFITS OF STENTING</span><span class="headingEndMark"> — </span>Late lumen loss and restenosis after non-stent interventions such as balloon angioplasty are caused by a combination of acute recoil, negative remodeling (arterial contraction) of the treated segment, and local neointimal hyperplasia (growth of tissue into the stent). In contrast, late lumen loss after stenting is almost exclusively due to in-stent neointimal hyperplasia as the main benefit of stents is to prevent vascular recoil and negative remodeling. Stents retain a larger acute lumen diameter that offsets the reduction in lumen diameter from neointimal hyperplasia. Stents have a low incidence of recoil. Drug-eluting stents (DES) reduce local neointimal hyperplasia [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/1587.html" rel="external">"Intracoronary stent restenosis", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H4232936840"><span class="h2">Drug-eluting stents</span><span class="headingEndMark"> — </span>DES reduce the rate of restenosis and target lesion revascularization compared with bare metal stents (BMS), which are no longer commonly used. The majority of DES consist of three components: a metallic alloy stent (predominantly cobalt chromium), a polymer coating (which may be durable or bioabsorbable), and an antirestenotic drug that is mixed within the polymer and is released over a period of weeks to months after implantation to reduce neointimal hyperplasia, the local proliferative healing response. DES types currently approved in the United States for use in the coronary circulation are shown in a table  (<a class="graphic graphic_table graphicRef65603" href="/z/d/graphic/65603.html" rel="external">table 1</a>). </p><p>There is strong evidence from randomized trials and large PCI registry databases that DES significantly lower the rate of target lesion revascularization compared with BMS. With regard to safety, the preponderance of evidence suggests that current-generation DES have similar rates of death and myocardial infarction (MI) to BMS. The risk of stent thrombosis with current-generation DES is similar to or possibly lower than BMS [<a href="#rid3">3-5</a>]. </p><p><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> is a macrocyclic triene antibiotic that has immunosuppressive and antiproliferative properties, and inhibits the intracellular mammalian target of rapamycin, thereby affecting cell cycle regulation. Sirolimus-eluting stents were first-generation devices developed to prevent the proliferation of smooth muscle cells and other cell types seen with restenosis after PCI. Sirolimus is incorporated into investigational stents, including polymer-free and bioabsorbable polymer devices. </p><p>Biologic characteristics of the four commercially available antirestenotic drugs (all of which are derivatives of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>) that have been used in DES include [<a href="#rid6">6</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> is a semi-synthetic <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> derivative in which the hydroxyl group at position C40 of sirolimus has been alkylated with a 2-hydroxyethyl group and that was shown in early small studies to be effective at preventing restenosis [<a href="#rid7">7</a>]. It is slightly more lipophilic than sirolimus, and therefore it is more rapidly absorbed into the arterial wall. Everolimus is in use in durable polymer and bioabsorbable polymer devices.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Zotarolimus is a derivative of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, in which the C40 position is modified by a tetrazole ring, resulting in a shorter circulating half-life of the drug. It is an equipotent analogue of sirolimus in vitro and in vivo and was specifically developed for delivery from DES. Similar to <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, the compound is highly lipophilic, which is favorable for cellular uptake.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ridaforolimus is a lipophilic <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> analogue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biolimus A9 is a highly lipophilic <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> analogue. </p><p></p><p>The length of time over which the drugs are eluted varies from 2 to 12 weeks and is presented in table form  (<a class="graphic graphic_table graphicRef65603" href="/z/d/graphic/65603.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3806951167"><span class="h2">Role for bare metal stents</span><span class="headingEndMark"> — </span>BMS are uncommonly used to treat coronary artery lesions, as DES are preferred for most patients. Some cardiac catheterization laboratories no longer have BMS for use in PCI. (See  <a class="medical medical_review" href="/z/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors", section on 'Comparison of DES and BMS'</a>.)</p><p>Circumstances in which implantation of a BMS may be reasonable:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients for whom it is known at the time of PCI that dual antiplatelet therapy (DAPT) cannot be used for at least 30 days. In this setting, some of our experts choose BMS while others place DES. There are no studies assessing safety of DES with less than 30 days of DAPT, but the use of DES in this setting is acceptable to some experts. The rationale is based on experimental data showing thromboresistance with current generation polymers, and with everolimus-eluting stents in particular, and extrapolation from the high bleeding risk trials showing at least similar safety of DES with only 30 days of DAPT. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients that require noncardiac surgery within four to six weeks of PCI. Within this interval, there is increased risk after BMS or DES. Some of our experts place BMS, while others place DES with temporary interruption of DAPT at the time of required surgery. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with active bleeding at the time of PCI or those at very high risk of bleeding while taking DAPT even for 30 days. </p><p></p><p class="headingAnchor" id="H348519696"><span class="h1">USE FOR SPECIFIC LESIONS OR PATIENTS</span><span class="headingEndMark"> — </span>The role of drug-eluting stents (DES) has been evaluated in specific clinical situations and populations. These are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Left main coronary artery disease or left anterior descending disease. (See  <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">"Left main coronary artery disease"</a> and  <a class="medical medical_review" href="/z/d/html/1544.html" rel="external">"Management of significant proximal left anterior descending coronary artery disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multivessel revascularization, ostial lesions, chronic total occlusion, long lesions (that may require overlapping stents), diffuse disease, bifurcation lesions, small coronary arteries, and intermediate (&lt;50 percent stenosis) lesions. (See  <a class="medical medical_review" href="/z/d/html/1571.html" rel="external">"Percutaneous coronary intervention of specific coronary lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PCI for ST-elevation MI (STEMI). (See  <a class="medical medical_review" href="/z/d/html/15358.html" rel="external">"Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Periprocedural management", section on 'Selection of stent type'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Saphenous vein graft stenosis. (See  <a class="medical medical_review" href="/z/d/html/1565.html" rel="external">"Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis", section on 'Outcomes with PCI'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with diabetes. (See  <a class="medical medical_review" href="/z/d/html/1581.html" rel="external">"Coronary artery revascularization in stable patients with diabetes mellitus", section on 'Stent type'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women. (See  <a class="medical medical_review" href="/z/d/html/1520.html" rel="external">"Management of coronary heart disease in women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients at high risk of bleeding. (See  <a class="medical medical_review" href="/z/d/html/108359.html" rel="external">"High bleeding risk patients undergoing percutaneous coronary intervention"</a>.) </p><p></p><p class="headingAnchor" id="H348519703"><span class="h1">OPTIMAL STENTING TECHNIQUE</span><span class="headingEndMark"> — </span>Coronary stents are delivered and deployed on balloon catheters  (<a class="graphic graphic_figure graphicRef52634" href="/z/d/graphic/52634.html" rel="external">figure 1</a>), which are inserted via the femoral, radial, or less commonly the brachial artery. Optimal stent deployment is necessary to minimize the likelihood of procedure complications and stent restenosis. When restenosis does occur with drug-eluting stents (DES), it is often a consequence of balloon barotrauma to the artery in areas not covered by the stent, gaps in stent coverage, inadequate stent expansion, or inability of the drug to limit neointimal hyperplasia [<a href="#rid8">8-14</a>]. The incidence and risk factors for DES restenosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1587.html" rel="external">"Intracoronary stent restenosis", section on 'Predictors in DES'</a> and  <a class="medical medical_review" href="/z/d/html/1587.html" rel="external">"Intracoronary stent restenosis", section on 'Incidence of restenosis'</a>.)</p><p>Coronary artery characteristics may interfere with optimal stent deployment:</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial diameter. Vessels smaller than 2 mm are not suitable for stenting. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tortuous, angulated, calcified, and chronically occluded arterial segments. These may prevent delivery of the stent to the target lesion, and severe calcification may prevent optimal stent expansion. </p><p></p><p>The single most important contribution to stenting efficacy is to achieve full expansion of the arterial lumen (so-called optimal stenting). Attainment of a large luminal diameter minimizes the risk of both stent thrombosis and restenosis [<a href="#rid15">15,16</a>]. Suboptimal luminal dilation is due to inadequate balloon expansion. This may be related to plaque characteristics, poor technique, or to stent elastic recoil, which is associated with stent design and resistance [<a href="#rid17">17</a>]. Stent expansion is estimated angiographically but can be quantified by intracoronary imaging techniques.</p><p>Another principle in the deployment of DES is to cover the entire lesion, as well as sites of balloon predilation, to cover all areas of balloon barotrauma. Multiple overlapping stents are sometimes required for diffusely diseased segments that cannot be treated adequately with a single stent. On the other hand, overlapping stents and longer total stent length are associated with an increased risk for restenosis. (See  <a class="medical medical_review" href="/z/d/html/1571.html" rel="external">"Percutaneous coronary intervention of specific coronary lesions", section on 'Overlapping stents'</a>.)</p><p>The following sections describe some components of stent delivery, deployment, and evaluation.</p><p class="headingAnchor" id="H742296139"><span class="h2">Predilation</span><span class="headingEndMark"> — </span>Predilation of the lesion is performed in most cases. Direct stenting without predilation, an alternative, may be reasonable based upon anticipated ease of delivery and deployment. Should predilation suggest that the lesion is not "dilatable," an alternative strategy of plaque modification such as atherectomy, high-pressure noncompliant balloon dilation, cutting or scoring balloons, lithoplasty or not placing a stent needs to be considered. Angiographic predictors of inability to predilate include moderate or severe coronary calcification, heavy plaque burden, or diffuse coronary artery disease. </p><p class="headingAnchor" id="H3345117839"><span class="h2">Direct stenting without predilation</span><span class="headingEndMark"> — </span>The availability of low-profile stent-delivery systems has led to the consideration of direct stenting (ie, without predilation). Although stenting reduces the incidence of restenosis after percutaneous transluminal coronary angioplasty, the classic approach of predilation, stent deployment, and high-pressure post-dilation is associated with increased procedure duration, more radiation exposure and contrast use, and increased cost compared with direct stenting [<a href="#rid18">18,19</a>].</p><p>Settings in which direct stenting might be considered include [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Vessel ≥2.5 mm in diameter</p><p class="bulletIndent1"><span class="glyph">●</span>Proximal lesion location</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of severe coronary calcification</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of significant angulation (bend &gt;45°)</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of very severe lesions and bifurcation lesions </p><p class="bulletIndent1"><span class="glyph">●</span>STEMI</p><p class="bulletIndent1"><span class="glyph">●</span>Saphenous vein grafts</p><p></p><p>A number of randomized clinical trials (BET, SWIBAP, PREDICT, CONVERTIBLE, and TRENDS) have compared direct stenting with stenting after balloon dilation [<a href="#rid20">20-24</a>]. Major outcomes were similar, including procedural success (although 6 to 14 percent of patients in the direct stenting group required predilation because of an inability to cross the lesion), adverse effects, and major cardiac events at follow-up. The authors of PREDICT concluded that direct stenting was safe and successful, but offered only modest cost savings and no reduction in late restenosis [<a href="#rid22">22</a>].</p><p>We favor predilation in most lesions. One possible exception is in degenerated saphenous vein grafts. In this situation, each balloon dilation is associated with a risk of embolization of degenerated graft material and obstruction of the coronary microcirculation and its consequences. If direct stenting is contemplated and it is unclear if the lesion is suitable or the correct stent sizing cannot be determined, intracoronary imaging such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT) can be performed to assist in decision making. </p><p class="headingAnchor" id="H831714015"><span class="h2">High-pressure balloon dilation</span><span class="headingEndMark"> — </span>A major strategy to attain optimal stent deployment is high-pressure balloon dilation during or after stent deployment. Studies show clear improvement in stent expansion and apposition with high-pressure dilation post-stenting [<a href="#rid25">25-27</a>]. These observations provided the basis for modern stenting techniques using routine high-pressure dilation in addition to antiplatelet therapy to prevent stent thrombosis. (See  <a class="medical medical_review" href="/z/d/html/1577.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies"</a>.)</p><p>Stents are usually deployed with a high-pressure technique utilizing ≥12 to 16 atmospheres (atm). Lower pressure deployment (8 to 14 atm) is indicated when there is significant vessel tapering or when proximal edge injury is a concern. In most cases, we perform high-pressure post-dilation with an appropriately sized noncompliant balloon at a minimum of 12 to 16 atm to achieve full stent expansion. </p><p class="headingAnchor" id="H955603330"><span class="h2">Intravascular ultrasound</span><span class="headingEndMark"> — </span>Intravascular ultrasound (IVUS; also called intracoronary ultrasound) is a diagnostic procedure that allows the operator to plan the stent procedure by determining the reference vessel diameter and lesion length, visualizing how well a stent is deployed by assessing stent expansion, and surveying for complications that occur at the edge of stents such as dissection [<a href="#rid25">25,28</a>]. Several studies have assessed the benefit of routine IVUS. (See  <a class="medical medical_review" href="/z/d/html/16536.html" rel="external">"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation", section on 'Intravascular ultrasound'</a>.)</p><p>Early studies of patients who received bare metal stents (BMS) suggested a reduction in the need for target vessel revascularization from routine IVUS guidance [<a href="#rid26">26,29</a>], but the results from subsequent randomized trials are conflicting [<a href="#rid30">30-34</a>]. </p><p>With regard to DES, a meta-analyses of seven randomized trials with 3192 patients comparing an IVUS- with angiographical-guided approach showed benefits of an IVUS-guided DES implantation at a mean of 15 months, including [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Lower risk of major adverse cardiac events (odds ratio [OR], 0.60; 95% CI 0.46-0.77)</p><p class="bulletIndent1"><span class="glyph">●</span>Lower risk of ischemia-driven target lesion revascularization (OR 0.60; 95% CI 0.43-0.84)</p><p class="bulletIndent1"><span class="glyph">●</span>Lower risk of stent thrombosis (OR 0.49; 95% CI 0.24-0.99)</p><p></p><p>The meta-analysis was updated by the investigators to include 10 randomized trials in 5060 patients and showed:</p><p class="bulletIndent1"><span class="glyph">●</span>Lower risk of cardiovascular death (OR 0.44, 95% CI 0.26-0.75)</p><p class="bulletIndent1"><span class="glyph">●</span>Lower risk of myocardial infarction (OR 0.55, 95% CI 0.32-0.94)</p><p></p><p>Despite the growing evidence in support of IVUS-guided PCI, the United States is low with a study of Medicare beneficiaries undergoing PCI, showing rates of use of 3 percent in 2009 and 6.9 percent in 2017 (p for trend &lt;0.001). Considerable variability was also shown in this study with more than half of hospitals using the technology &lt;1 percent and only 12 percent of hospitals using IVUS more that 10 percent [<a href="#rid36">36</a>]. The barriers to adoption include lack of understanding of the optimal methods to use the technology during PCI, procedural time and cost, and lack of availability in some interventional laboratories. Currently, the ACC/AHA revascularization guidelines provide a class IIb recommendation and suggest IVUS when underexpansion is suspected on coronary angiography, with long lesions, when the final size goal is uncertain, or when stent expansion is expected to be difficult, as with calcified lesions or a lesion in the left main coronary artery [<a href="#rid37">37</a>]. Certainly, techniques to optimize stent results such as postdeployment high-pressure dilation should be routine in most cases, but it is advisable that PCI operators are trained and have IVUS or OCT available for cases where optimal stent expansion or sizing is uncertain.</p><p>In patients with prior stent placement, IVUS or OCT is recommended if stent failure is identified. Mechanisms of restenosis or thrombosis can be determined, including stent underexpansion, intimal hyperplasia, neoatherosclerosis, malapposition, edge dissection, or adjacent inflow or outflow lesions related to disease progression. Treatment is guided by the findings and may include balloon angioplasty, DES, drug-eluting balloon (if available), atherectomy, brachytherapy, or coronary artery bypass grafting.</p><p class="headingAnchor" id="H1608153248"><span class="h2">Optical coherence tomography</span><span class="headingEndMark"> — </span>OCT has a higher spatial resolution than IVUS and is more useful for assessing stent apposition and strut coverage during follow-up imaging. Both techniques may be useful for guiding optimal stent deployment [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/16536.html" rel="external">"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation", section on 'Optical coherence tomography'</a>.)</p><p class="headingAnchor" id="H4001370426"><span class="h2">Coronary flow reserve measurements</span><span class="headingEndMark"> — </span>Coronary artery Doppler measurements can be used to assess whether optimal stenting has been achieved. Two measurements have been evaluated: the relative coronary flow velocity reserve and the coronary pressure-derived myocardial fractional flow reserve (FFRmyo). Although these methods are useful to predict optimal stent results and predict future events, they are seldom used for this purpose. Most operators rely on angiographic appearance or IVUS. (See <a class="local">'Intravascular ultrasound'</a> above.) </p><p>The coronary pressure-derived FFRmyo compares the intracoronary pressure distal to the stented site (measured with a specially designed angioplasty guidewire) with the aortic root pressure measured through the guiding catheter during maximal hyperemic flow produced by bolus intracoronary <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> injection or a continuous intravenous infusion. It is an easy, inexpensive, and rapidly obtainable index. (See  <a class="medical medical_review" href="/z/d/html/1514.html" rel="external">"Clinical use of coronary artery pressure flow measurements"</a>.)</p><p>The prognostic effect of the FFRmyo has been demonstrated in several studies [<a href="#rid39">39-41</a>]. In the largest series, FFRmyo was measured in 750 patients who had undergone apparently satisfactory stent implantation [<a href="#rid39">39</a>]. At six months, adverse cardiac events occurred in 10 percent, primarily target vessel revascularization (70 percent) and MI (25 percent). By multivariate analysis, the FFR was the major independent predictor of adverse events. At a normal FFR (&gt;0.95), adverse events occurred in 4.9 percent compared with 6.2, 20.3, and 29.5 percent, respectively, for FFR between 0.90 and 0.95 (&lt;0.9 and &lt;0.80).</p><p class="headingAnchor" id="H3237810699"><span class="h1">ADJUNCTIVE MEDICAL THERAPY</span></p><p class="headingAnchor" id="H2041783870"><span class="h2">Antithrombotic therapy</span><span class="headingEndMark"> — </span>All patients undergoing PCI are given combined anticoagulant and antiplatelet therapy [<a href="#rid37">37,42</a>]. The data supporting the use of these drugs and the recommended regimen are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1577.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies"</a> and  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a>.)</p><p>Almost all patients are discharged on dual antiplatelet therapy (DAPT) after placement of an intracoronary stent. After a period of DAPT, most patients continue on single antiplatelet therapy. (See  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Our approach'</a>.)</p><p class="headingAnchor" id="H4230853172"><span class="h2">Statin therapy</span><span class="headingEndMark"> — </span>Statin therapy improves the outcome of patients with either stable or unstable coronary disease treated medically. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome"</a>.)</p><p>A benefit from statin therapy at the time of PCI has also been demonstrated, as established below.</p><p class="headingAnchor" id="H3772653516"><span class="h3">Before percutaneous coronary intervention</span><span class="headingEndMark"> — </span>Benefit from statin therapy prior to PCI, as evidenced by a reduction in periprocedural MI, has been shown in multiple randomized trials [<a href="#rid43">43-48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The benefit from initiation of statin therapy prior to PCI in patients with acute coronary syndrome was evaluated in the ARMYDA-ACS trial of 171 patients with non-ST elevation MI scheduled to undergo urgent (but not emergent) PCI [<a href="#rid48">48</a>]. The patients were randomly assigned to either 80 mg of <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> 12 hours before the procedure with an additional preprocedural dose of 40 mg, or to matching placebo; all patients received 40 mg of atorvastatin daily thereafter. The primary outcome of 30-day major adverse cardiac events (eg, death, MI, or unplanned revascularization) occurred significantly less often in the early atorvastatin group (5 versus 17 percent, odds ratio 0.12, 95% CI 0.05-0.50). The difference was due almost entirely to a lowering of the incidence of MI, defined as important creatine kinase MB fraction (CK-MB) elevation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the ARMYDA trial, 153 stable patients were randomly assigned to <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> 40 mg/day or placebo starting seven days before the procedure [<a href="#rid43">43</a>]. Cardiac biomarkers were measured at baseline and at 8 and 24 hours after the procedure. Patients pretreated with atorvastatin had a significantly lower incidence of myocardial injury as detected by elevation in serum CK-MB (12 versus 35 percent) and troponin I (20 versus 48 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the open label NAPLES II trial, 668 stable, statin-naive patients were randomly assigned to either <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> 80 or no therapy 24 hours before PCI [<a href="#rid47">47</a>]. Cardiac biomarkers were measured at baseline and at 8 and 24 hours after the procedure. The primary end point of periprocedural MI (CK-MB elevation &gt;3 X upper limit of normal) was significantly lower in the atorvastatin group (9.5 versus 15.8 percent; odds ratio 0.56, 95% CI 0.36-0.89).</p><p></p><p class="headingAnchor" id="H4011623688"><span class="h3">After percutaneous coronary intervention</span><span class="headingEndMark"> — </span>Statin therapy has both short- and long-term benefits when administered after PCI with stenting [<a href="#rid49">49-51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The PROVE-IT TIMI 22 trial demonstrated that the use of intensive statin therapy (<a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> 80 mg), as opposed to less intensive therapy (<a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> 40 mg), after PCI in patients with acute coronary syndromes resulted in a significantly lower combined rate of all-cause mortality, MI, unstable angina, and revascularization after 30 days (21.5 versus 26.5 percent) [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome", section on 'Timing of initiation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the LIPS trial, 1677 patients with stable or unstable angina or silent ischemia with serum total cholesterol between 135 and 270 mg/dL (3.5 to 7.0 mmol/L) were randomly assigned to <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> (80 mg/day) or placebo after successful completion of their first PCI [<a href="#rid50">50</a>]. At a median follow-up of 3.9 years, fluvastatin therapy was associated with a significant reduction in major adverse cardiac events, defined as any cardiac death, nonfatal MI, or a reintervention procedure (21.4 versus 26.7 percent). The benefit began at 1.5 years, was independent of baseline serum total cholesterol, and was seen in diabetics and those with multivessel disease. </p><p></p><p>There was no evidence of a reduction in restenosis in the LIPS trial. Thus, the benefit appeared to be unrelated to the stent site, and may have been due to actions (such as plaque stabilization) elsewhere in the coronary circulation. (See  <a class="medical medical_review" href="/z/d/html/4546.html" rel="external">"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease"</a>.)</p><p>The issue of whether patients on chronic statin therapy scheduled to undergo PCI benefit from an acute dose of statin was addressed in the ARMYDA-RECAPTURE trial [<a href="#rid52">52</a>]. In this study, 383 patients (53 percent of whom had stable angina) were randomly assigned to either <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> reload (80 mg 12 hours before the intervention, with a further 40 mg preprocedure dose) or placebo. The primary end point of 30-day major adverse cardiovascular events (eg, cardiac death, MI, or unplanned revascularization) occurred significantly less often in the atorvastatin reload group (3.7 versus 9.4 percent), driven mostly by a reduction in periprocedural MI. In subset analysis, the benefit was seen principally in patients with acute coronary syndrome (3.3 versus 14.8 percent), but not in those with stable angina (4.0 versus 4.9 percent). Whether routine reloading with a statin should be considered standard of care is yet to be determined. (See  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome"</a>.) </p><p class="headingAnchor" id="H4156699413"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>A variety of periprocedural complications (both cardiac and noncardiac) can occur after PCI with stenting. These issues are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention"</a>.)</p><p class="headingAnchor" id="H7647664"><span class="h1">ANTIMICROBIAL PROPHYLAXIS</span><span class="headingEndMark"> — </span>Placement of drug-eluting coronary stents is not an indication for antimicrobial prophylaxis before dental or invasive procedures [<a href="#rid53">53</a>]. </p><p class="headingAnchor" id="H2215613215"><span class="h1">TIMING OF DISCHARGE</span><span class="headingEndMark"> — </span>We believe it is reasonable to discharge elective, lower-risk patients following uncomplicated, lower complexity PCI after four to eight hours of observation on the day of PCI if no complications or concerns have arisen. </p><p>A 2013 meta-analysis of five randomized trials (2039 patients) and eight observational studies (109,791 patients) with substantial heterogeneity compared same-day discharge (SDD) with overnight hospitalization (ON) [<a href="#rid54">54</a>]. Most patients were at low risk of a complication: Very few had an acute coronary syndrome, many had single vessel disease, and most did not have an intraprocedural complication [<a href="#rid55">55</a>]. The primary outcomes were the incidence of total complications, major adverse cardiovascular events, and rehospitalization within 30 days. With regard to the incidence of total complications within 30 days, there was no significant difference between SDD and ON in either the randomized trials or observational studies (odds ratio 1.2, 95% CI 0.82-1.74 and 0.67, 95% CI 0.27-1.66, comparing SDD with ON, respectively). There was no significant difference between the two approaches with regard to major adverse cardiovascular events or rehospitalization.</p><p class="headingAnchor" id="H1504703410"><span class="h1">SAFETY OF MRI</span><span class="headingEndMark"> — </span>Any ferromagnetic object within the body represents a potential hazard when exposed to the strong magnetic field of a magnetic resonance imaging (MRI) system. Based upon available evidence, it appears to be safe to perform an MRI at any time after placement of coronary artery stents of any type. The discussion of this issue is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113084.html" rel="external">"Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging", section on 'Arterial stents, coils, and clips'</a>.)</p><p class="headingAnchor" id="H2859995525"><span class="h1">RISK OF EARLY NONCARDIAC SURGERY</span><span class="headingEndMark"> — </span>Studies in patients receiving bare metal stents have shown that major noncardiac surgery within six weeks (and particularly within two weeks) of stenting is associated with an appreciable risk of stent thrombosis that is often associated with cessation of or a reduction in antiplatelet therapy to minimize bleeding risk. Limited data for drug-eluting stents suggest a similar risk. In contrast, balloon angioplasty alone appears to be associated with a low incidence of cardiac death or MI when performed a few weeks before noncardiac surgery. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/86233.html" rel="external">"Noncardiac surgery after percutaneous coronary intervention", section on 'Our approach'</a>.) </p><p class="headingAnchor" id="H348519248"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86375.html" rel="external">"Patient education: Stenting for the heart (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3444.html" rel="external">"Patient education: Angina treatment — medical versus interventional therapy (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3434.html" rel="external">"Patient education: Stenting for the heart (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background </strong>– Stents should be deployed with a goal of achieving minimal residual stenosis (so-called optimal stenting). Attainment of a large luminal diameter minimizes the risk of both stent thrombosis and restenosis. (See <a class="local">'Optimal stenting technique'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optimal stenting technique</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Predilation – Although direct stenting has some advantages, predilation is recommended for the majority of lesions  (<a class="graphic graphic_figure graphicRef52634" href="/z/d/graphic/52634.html" rel="external">figure 1</a>). (See <a class="local">'Predilation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-pressure balloon dilation – In most cases, we perform high-pressure stent deployment or post-dilation at 12 to 16 atm to achieve full stent expansion. (See <a class="local">'High-pressure balloon dilation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravascular ultrasound or optical coherence tomography – These can be useful adjuncts to guide stent placement. The routine use of one of these imaging tools (in addition to the use of a high-pressure balloon postdilation) after second-generation drug-eluting stent (DES) should be considered based on a growing body of evidence, particularly in complex PCI and if there is any question about optimal results or for stent failure (thrombosis or restenosis). (See <a class="local">'Intravascular ultrasound'</a> above and <a class="local">'Optical coherence tomography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statin therapy </strong>– This improves the outcome of patients with either stable or unstable coronary disease treated medically. Virtually all patients undergoing percutaneous coronary intervention should be on chronic statin therapy. The role of statin reloading remains unclear. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of discharge </strong>– Patients undergoing elective stent therapy are generally discharged within 24 hours after stent implantation following overnight observation and monitoring. Same-day discharge may be appropriate for elective patients who have an uncomplicated procedure and are at low risk of out-of-hospital complication. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ohya M, Kadota K, Kubo S, et al. Incidence, predictive factors, and clinical impact of stent recoil in stent fracture lesion after drug-eluting stent implantation. Int J Cardiol 2016; 214:123.</a></li><li><a class="nounderline abstract_t">Koo BK, Waseda K, Ako J, et al. Incidence of diffuse and focal chronic stent recoil after implantation of current generation bare-metal and drug-eluting stents. Int J Cardiol 2010; 144:132.</a></li><li><a class="nounderline abstract_t">Räber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011; 123:2819.</a></li><li><a class="nounderline abstract_t">Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011; 58:1569.</a></li><li><a class="nounderline abstract_t">Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125:2873.</a></li><li><a class="nounderline abstract_t">Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013; 368:254.</a></li><li><a class="nounderline abstract_t">Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004; 109:2168.</a></li><li><a class="nounderline abstract_t">Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111:2257.</a></li><li><a class="nounderline abstract_t">Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.</a></li><li><a class="nounderline abstract_t">Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093.</a></li><li><a class="nounderline abstract_t">Carrozza JP Jr. Sirolimus-eluting stents: does a great stent still need a good interventionalist? J Am Coll Cardiol 2004; 43:1116.</a></li><li><a class="nounderline abstract_t">Lemos PA, Saia F, Ligthart JM, et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003; 108:257.</a></li><li><a class="nounderline abstract_t">Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 2004; 109:1085.</a></li><li><a class="nounderline abstract_t">Takebayashi H, Kobayashi Y, Mintz GS, et al. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. Am J Cardiol 2005; 95:498.</a></li><li><a class="nounderline abstract_t">Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.</a></li><li><a class="nounderline abstract_t">Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.</a></li><li><a class="nounderline abstract_t">Bermejo J, Botas J, García E, et al. Mechanisms of residual lumen stenosis after high-pressure stent implantation: a quantitative coronary angiography and intravascular ultrasound study. Circulation 1998; 98:112.</a></li><li><a class="nounderline abstract_t">Briguori C, Sheiban I, De Gregorio J, et al. Direct coronary stenting without predilation. J Am Coll Cardiol 1999; 34:1910.</a></li><li><a class="nounderline abstract_t">Wilson SH, Berger PB, Mathew V, et al. Immediate and late outcomes after direct stent implantation without balloon predilation. J Am Coll Cardiol 2000; 35:937.</a></li><li><a class="nounderline abstract_t">Carrié D, Khalifé K, Citron B, et al. Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris. BET (Benefit Evaluation of Direct Coronary Stenting) Study Group. Am J Cardiol 2001; 87:693.</a></li><li><a class="nounderline abstract_t">Le Breton H, Boschat J, Commeau P, et al. Randomised comparison of coronary stenting with and without balloon predilatation in selected patients. Heart 2001; 86:302.</a></li><li><a class="nounderline abstract_t">Baim DS, Flatley M, Caputo R, et al. Comparison of PRE-dilatation vs direct stenting in coronary treatment using the Medtronic AVE S670 Coronary Stent System (the PREDICT trial). Am J Cardiol 2001; 88:1364.</a></li><li><a class="nounderline abstract_t">Wijns W, Verheye S, Manoharan G, et al. Angiographic, intravascular ultrasound, and fractional flow reserve evaluation of direct stenting vs. conventional stenting using BeStent2 in a multicentre randomized trial. Eur Heart J 2005; 26:1852.</a></li><li><a class="nounderline abstract_t">Dawkins KD, Chevalier B, Suttorp MJ, et al. Effectiveness of "direct" stenting without balloon predilatation (from the Multilink Tetra Randomised European Direct Stent Study [TRENDS]). Am J Cardiol 2006; 97:316.</a></li><li><a class="nounderline abstract_t">Nakamura S, Colombo A, Gaglione A, et al. Intracoronary ultrasound observations during stent implantation. Circulation 1994; 89:2026.</a></li><li><a class="nounderline abstract_t">Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91:1676.</a></li><li><a class="nounderline abstract_t">Dirschinger J, Kastrati A, Neumann FJ, et al. Influence of balloon pressure during stent placement in native coronary arteries on early and late angiographic and clinical outcome: A randomized evaluation of high-pressure inflation. Circulation 1999; 100:918.</a></li><li><a class="nounderline abstract_t">Goldberg SL, Colombo A, Nakamura S, et al. Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents. J Am Coll Cardiol 1994; 24:996.</a></li><li><a class="nounderline abstract_t">Albiero R, Rau T, Schlüter M, et al. Comparison of immediate and intermediate-term results of intravascular ultrasound versus angiography-guided Palmaz-Schatz stent implantation in matched lesions. Circulation 1997; 96:2997.</a></li><li><a class="nounderline abstract_t">Fitzgerald PJ, Oshima A, Hayase M, et al. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. Circulation 2000; 102:523.</a></li><li><a class="nounderline abstract_t">Frey AW, Hodgson JM, Müller C, et al. Ultrasound-guided strategy for provisional stenting with focal balloon combination catheter: results from the randomized Strategy for Intracoronary Ultrasound-guided PTCA and Stenting (SIPS) trial. Circulation 2000; 102:2497.</a></li><li><a class="nounderline abstract_t">Schiele F, Meneveau N, Vuillemenot A, et al. Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies--with and without intravascular ultrasound guidance. RESIST Study Group. REStenosis after Ivus guided STenting. J Am Coll Cardiol 1998; 32:320.</a></li><li><a class="nounderline abstract_t">Mudra H, di Mario C, de Jaegere P, et al. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). Circulation 2001; 104:1343.</a></li><li><a class="nounderline abstract_t">Russo RJ, Silva PD, Teirstein PS, et al. A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial). Circ Cardiovasc Interv 2009; 2:113.</a></li><li><a class="nounderline abstract_t">Elgendy IY, Mahmoud AN, Elgendy AY, Bavry AA. Outcomes With Intravascular Ultrasound-Guided Stent Implantation: A Meta-Analysis of Randomized Trials in the Era of Drug-Eluting Stents. Circ Cardiovasc Interv 2016; 9:e003700.</a></li><li><a class="nounderline abstract_t">Mentias A, Sarrazin MV, Saad M, et al. Long-Term Outcomes of Coronary Stenting With and Without Use of Intravascular Ultrasound. JACC Cardiovasc Interv 2020; 13:1880.</a></li><li><a class="nounderline abstract_t">Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.</a></li><li><a class="nounderline abstract_t">Kubo T, Shinke T, Okamura T, et al. Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results. Eur Heart J 2017; 38:3139.</a></li><li><a class="nounderline abstract_t">Pijls NH, Klauss V, Siebert U, et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation 2002; 105:2950.</a></li><li><a class="nounderline abstract_t">Fearon WF, Luna J, Samady H, et al. Fractional flow reserve compared with intravascular ultrasound guidance for optimizing stent deployment. Circulation 2001; 104:1917.</a></li><li><a class="nounderline abstract_t">Berger A, Botman KJ, MacCarthy PA, et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. J Am Coll Cardiol 2005; 46:438.</a></li><li><a class="nounderline abstract_t">Popma JJ, Ohman EM, Weitz J, et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001; 119:321S.</a></li><li><a class="nounderline abstract_t">Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110:674.</a></li><li><a class="nounderline abstract_t">Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004; 25:1822.</a></li><li><a class="nounderline abstract_t">Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106:2180.</a></li><li><a class="nounderline abstract_t">Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006; 48:1560.</a></li><li><a class="nounderline abstract_t">Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54:2157.</a></li><li><a class="nounderline abstract_t">Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49:1272.</a></li><li><a class="nounderline abstract_t">Gibson CM, Pride YB, Hochberg CP, et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009; 54:2290.</a></li><li><a class="nounderline abstract_t">Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287:3215.</a></li><li><a class="nounderline abstract_t">Schömig A, Mehilli J, Holle H, et al. Statin treatment following coronary artery stenting and one-year survival. J Am Coll Cardiol 2002; 40:854.</a></li><li><a class="nounderline abstract_t">Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009; 54:558.</a></li><li><a class="nounderline abstract_t">Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.</a></li><li><a class="nounderline abstract_t">Abdelaal E, Rao SV, Gilchrist IC, et al. Same-day discharge compared with overnight hospitalization after uncomplicated percutaneous coronary intervention: a systematic review and meta-analysis. JACC Cardiovasc Interv 2013; 6:99.</a></li><li><a class="nounderline abstract_t">Mavromatis K. Same-day discharge after percutaneous coronary intervention: are we ready? JACC Cardiovasc Interv 2013; 6:113.</a></li></ol></div><div id="topicVersionRevision">Topic 1569 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060271" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence, predictive factors, and clinical impact of stent recoil in stent fracture lesion after drug-eluting stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171393" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence of diffuse and focal chronic stent recoil after implantation of current generation bare-metal and drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21646500" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21924575" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586281" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23323902" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Drug-eluting coronary-artery stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123533" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867193" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Molecular basis of restenosis and drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523139" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14550694" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028376" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sirolimus-eluting stents: does a great stent still need a good interventionalist?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860901" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993129" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695138" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041414" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041413" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9679716" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mechanisms of residual lumen stenosis after high-pressure stent implantation: a quantitative coronary angiography and intravascular ultrasound study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588203" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Direct coronary stenting without predilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10732891" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immediate and late outcomes after direct stent implantation without balloon predilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11249885" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris. BET (Benefit Evaluation of Direct Coronary Stenting) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11514483" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Randomised comparison of coronary stenting with and without balloon predilatation in selected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11741553" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of PRE-dilatation vs direct stenting in coronary treatment using the Medtronic AVE S670 Coronary Stent System (the PREDICT trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888499" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Angiographic, intravascular ultrasound, and fractional flow reserve evaluation of direct stenting vs. conventional stenting using BeStent2 in a multicentre randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442388" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effectiveness of "direct" stenting without balloon predilatation (from the Multilink Tetra Randomised European Direct Stent Study [TRENDS]).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181126" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intracoronary ultrasound observations during stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7882474" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468521" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Influence of balloon pressure during stent placement in native coronary arteries on early and late angiographic and clinical outcome: A randomized evaluation of high-pressure inflation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7930236" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386168" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of immediate and intermediate-term results of intravascular ultrasound versus angiography-guided Palmaz-Schatz stent implantation in matched lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10920064" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11076823" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ultrasound-guided strategy for provisional stenting with focal balloon combination catheter: results from the randomized Strategy for Intracoronary Ultrasound-guided PTCA and Stenting (SIPS) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708456" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies--with and without intravascular ultrasound guidance. RESIST Study Group. REStenosis after Ivus guided STenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560848" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031704" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980883" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Outcomes With Intravascular Ultrasound-Guided Stent Implantation: A Meta-Analysis of Randomized Trials in the Era of Drug-Eluting Stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32819477" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long-Term Outcomes of Coronary Stenting With and Without Use of Intravascular Ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22064601" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29121226" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081986" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602494" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fractional flow reserve compared with intravascular ultrasound guidance for optimizing stent deployment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16053955" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157657" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antithrombotic therapy in patients undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277322" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15474697" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390944" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17045888" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19664895" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17394957" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958964" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12076217" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12225707" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Statin treatment following coronary artery stenting and one-year survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643320" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446442" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352820" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Same-day discharge compared with overnight hospitalization after uncomplicated percutaneous coronary intervention: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352821" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Same-day discharge after percutaneous coronary intervention: are we ready?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
